Terminated PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT03752099

To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

A Phase 1b/2 Study to Evaluate the Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Sponsor: Veru Inc.

Conditions Metastatic Castration Resistant Prostate Cancer

Interventions VERU-111

Updated 25 times since 2018 Last updated: Sep 22, 2023 Started: Jan 18, 2019 Primary completion: Mar 15, 2023 Completion: Mar 15, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Administrative decision

Other terminated trials from Veru Inc.

More terminations from Veru Inc.

Other Metastatic Castration Resistant Prostate Cancer trials with similar outcome

Browse all Metastatic Castration Resistant Prostate Cancer trials

Listed as NCT03752099, this PHASE1/PHASE2 trial focuses on Metastatic Castration Resistant Prostate Cancer and remains terminated or withdrawn. Sponsored by Veru Inc., it has been updated 25 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

25 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Oct 2023 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2

Status: Completed → Terminated
Jul 2023 — Oct 2023 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed
May 2023 — Jul 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2

▶ Show 20 earlier versions

Apr 2023 — May 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2023 — Apr 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Apr 2022 — Jan 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2022 — Apr 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Oct 2021 — Jan 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Sep 2021 — Oct 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE1_PHASE2
Apr 2021 — Jun 2021 [monthly]

Recruiting PHASE1_PHASE2
Mar 2021 — Apr 2021 [monthly]

Recruiting PHASE1_PHASE2
Jan 2021 — Mar 2021 [monthly]

Recruiting PHASE1_PHASE2
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2
Sep 2020 — Nov 2020 [monthly]

Recruiting PHASE1_PHASE2
Dec 2019 — Sep 2020 [monthly]

Recruiting PHASE1_PHASE2
Oct 2019 — Dec 2019 [monthly]

Recruiting PHASE1_PHASE2
Jul 2019 — Oct 2019 [monthly]

Recruiting PHASE1_PHASE2
May 2019 — Jul 2019 [monthly]

Recruiting PHASE1_PHASE2
Apr 2019 — May 2019 [monthly]

Recruiting PHASE1_PHASE2
Mar 2019 — Apr 2019 [monthly]

Recruiting PHASE1_PHASE2
Feb 2019 — Mar 2019 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2018 — Feb 2019 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Veru Inc.

Data source: Veru Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bala-Cynwyd, United States , Baltimore, United States , Canton, United States , Dallas, United States , Golden, United States , Houston, United States , Jeffersonville, United States , Miami, United States , San Antonio, United States , Shreveport, United States and 3 more locations